Pulmonary tuberculosis vaccine, preparation method therefor, and application thereof
Patent Information
- Application Number
- MYPI2025005484
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-15
- Filing Date
- 2024-03-15
- Publication Date
- 2024-09-15
AI Technical Summary
Existing tuberculosis vaccines such as BCG are insufficient in terms of protection and scope of use, and cannot effectively prevent adults from being infected by Mycobacterium tuberculosis, resulting in tuberculosis continuing to ravage the world.
Develop a recombinant adenovirus vector tuberculosis vaccine that combines multiple antigens of Mycobacterium tuberculosis, such as Mtb32A, Mtb39A and Ag85A, to form the fusion antigen TB75K, and uses recombinant adenovirus vector technology to prepare the vaccine, using mucosal administration to improve immune response.
The vaccine can effectively clear tuberculosis bacteria at the infection site, enhance the body's cellular immunity and mucosal immune response, provide more lasting protection, solve the problem of reduced protective power of existing vaccines in adults, and achieve more through mucosal administration. Low dose, highly effective immune effect.
Smart Images

Figure PI2025005484_DRAWING_001 
Figure PI2025005484_DRAWING_002 
Figure PI2025005484_DRAWING_003
Abstract
Description
A tuberculosis vaccine and its preparation method and application Technical Field
[0001] The present invention relates to the field of vaccine technology, and specifically to a tuberculosis vaccine, a preparation method thereof, and an application thereof, a recombinant adenovirus vector tuberculosis vaccine, a preparation method thereof, and an application thereof, and more specifically to a preparation method and an application thereof of a recombinant adenovirus vector tuberculosis vaccine for mucosal administration. Background Art
[0002] Tuberculosis (TB), caused by Mycobacterium tuberculosis (TB), is the leading bacterial infection causing the most deaths worldwide. As an ancient disease, TB has been a pandemic for nearly a century. Approximately a quarter of the global population is infected with TB, and the disease kills over 1.5 million people annually. Vaccination is the most effective, low-burden prevention and treatment measure for TB. However, since the introduction of Bacillus Calmette-Guérin (BCG) in 1921, no new TB vaccines have been marketed in the past 100 years. While BCG is inexpensive, safe, and effective in preventing TB in children after neonatal administration, extensive research indicates that its protection against TB only lasts for approximately 10 years. Protection decreases with age, and BCG is ineffective in preventing infection with M. tuberculosis and TB disease in adults. Despite widespread BCG vaccination worldwide, the lack of a superior alternative vaccine means that TB continues to wreak havoc worldwide. A vaccine that can prevent tuberculosis infection and / or prevent the reactivation of latent tuberculosis is the most effective means of controlling tuberculosis that is urgently needed by the global public health system.
[0003] Summary of the Invention
[0004] Based on previous research, the present invention has developed an immune composition that effectively enhances the body's immune response, overcoming the shortcomings of existing tuberculosis vaccines in terms of protection and scope of application. It promptly eliminates tuberculosis bacteria at the site of infection, controls latent infection, and achieves infection prevention. The immune composition of the present invention includes multiple antigens of Mycobacterium tuberculosis; these antigens do not interfere with each other's expression and simultaneously enhance the immune response generated by each antigen. This composition effectively stimulates both cellular and mucosal immunity at high levels.
[0005] The term "TB75K" in the present invention refers to the immunogenic Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A)
[0006] An immunogenic composition comprises Mycobacterium tuberculosis Mtb32A antigen or an immunogenic fragment thereof, Mtb39A antigen or an immunogenic fragment thereof and Ag85A antigen or an immunogenic fragment thereof.
[0007] Furthermore, Mtb32A and Mtb39A are fusion antigens (TB75K).
[0008] Furthermore, Mtb32A, Mtb39A and Ag85A are fusion antigens.
[0009] Furthermore, Ag85A is fused with Mtb32A and Mtb39A (TB75K) via a linker; preferably, it is Ag85A-linker-TB75K or TB75K-linker-Ag85A.
[0010] Exemplarily, the amino acid sequence of the Ag85A antigen is SEQ ID NO: 1 or a sequence having at least 75% homology; preferably, at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology.
[0011] Exemplarily, the amino acid sequence of the Mtb32A and Mtb39A fusion antigen (abbreviated as TB75K) is SEQ ID NO: 2 or a sequence having at least 75% homology; preferably, at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology;
[0012] Exemplarily, the amino acid sequence of the Ag85A-linker-TB75K antigen is SEQ ID NO: 3 or a sequence having at least 75% homology; preferably, at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology; more preferably, the linker sequence can be replaced.
[0013] Specifically, the linker is a flexible linker, and the connecting peptide of its sequence is GGGGSGGGGSGGGGS (SEQ ID NO: 6) connecting peptide, GGGGS (SEQ ID NO: 7) connecting peptide, GGGGGGGG (SEQ ID NO: 8) connecting peptide, GGGGGG (SEQ ID NO: 9) connecting peptide, EAAAKEAAAK (SEQ ID NO: 10) connecting peptide, EAAAK (SEQ ID NO: 11) connecting peptide, PAPAP (SEQ ID NO: 12) connecting peptide, APAPAPAPAPAPAPAP (SEQ ID NO: 13) connecting peptide, KESGSVSSEQLAQFRSLD (SEQ ID NO: 14) connecting peptide, AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAK (SEQ ID NO: 15) connecting peptide, EAAAKA (SEQ ID NO: 32) and / or EAAAKEAAAKEAAAK (SEQ ID NO: 5) connecting peptide; more preferably, the linker is as shown in SEQ ID NO: shown in 5-15.
[0014] Specifically, the amino acid sequence encoding the TB75K-linker-Ag85A antigen is SEQ ID NO: 4 or a sequence with at least 75% homology; preferably, it has at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homology; more preferably, the linker sequence can be replaced.
[0015] Specifically, the linker is a flexible linker, and the connecting peptide of its sequence is GGGGSGGGGSGGGGS (SEQ ID NO: 6) connecting peptide, GGGGS (SEQ ID NO: 7) connecting peptide, GGGGGGGG (SEQ ID NO: 8) connecting peptide, GGGGGG (SEQ ID NO: 9) connecting peptide, EAAAKEAAAK (SEQ ID NO: 10) connecting peptide, EAAAK (SEQ ID NO: 11) connecting peptide, PAPAP (SEQ ID NO: 12) connecting peptide, APAPAPAPAPAPAPAP (SEQ ID NO: 13) connecting peptide, KESGSVSSEQLAQFRSLD (SEQ ID NO: 14) connecting peptide, AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAK (SEQ ID NO: 15) connecting peptide, EAAAKA (SEQ ID NO: 32) and / or EAAAKEAAAKEAAAK (SEQ ID NO: 5) connecting peptide; more preferably, the linker is as shown in SEQ ID NO: shown in 5-15.
[0016] Furthermore, the immunogenic composition includes a signal peptide; preferably, the signal peptide is selected from one or more of tissue plasminogen activator (tPa) signal peptide, Ag85A wild-type signal peptide, growth hormone signal peptide, recombinant human tumour inhibitor M (human OSM), vesicular stomatitis virus fusogenic coat G glycoprotein (VSV-G), mouse Ig Kappa, mouse heavy chain, basement membrane protein 40 (BM40), human chymotrypsinogen, human trypsinogen-2, human interleukin-2 (human IL-2), luciferase, human serum albumin (HSA), influenza hemagglutinin, human insulin, and silkworm fibrin LC, more preferably, the amino acid sequence encoding the signal peptide is as shown in SEQ ID NO: 16-30. Specifically, the above immunogenic composition is used to prepare a drug for preventing and / or treating a disease; preferably, the disease is pulmonary tuberculosis.
[0017] One aspect of the present invention provides a use of an immunogenic composition in the preparation of a medicament for preventing and / or treating a disease; preferably, the disease is pulmonary tuberculosis.
[0018] Another aspect of the present invention further provides a polynucleotide molecule, including a nucleic acid molecule encoding the above-mentioned Ag85A antigen or immunogenic fragment, a nucleic acid molecule encoding the Mtb32A antigen or immunogenic fragment, and a nucleic acid molecule encoding the Mtb39A antigen or immunogenic fragment.
[0019] Another aspect of the present invention further provides the use of the above-mentioned polynucleotide molecules in the preparation of drugs for preventing and / or treating diseases; preferably, the disease is pulmonary tuberculosis.
[0020] Another aspect of the present invention provides a vector containing the above-mentioned polynucleotide molecule.
[0021] Another aspect of the present invention further provides the use of the above-mentioned vector in the preparation of a medicament for preventing and / or treating a disease; preferably, the disease is pulmonary tuberculosis. In another aspect of the present invention, preferably, the vector is a replication-deficient recombinant adenovirus. The adenovirus is a human adenovirus or a chimpanzee adenovirus; preferably, the human adenovirus is selected from one or more of serotypes 1 to 57; more preferably, the human adenovirus is serotype 5, 26, or 35.
[0022] Another aspect of the present invention provides a method for preparing a recombinant adenovirus, the method comprising the following steps:
[0023] (1) constructing a shuttle plasmid vector containing the polynucleotide encoding the tuberculosis antigen peptide or structural protein;
[0024] (2) transfecting the shuttle plasmid vector and the backbone plasmid described in step (1) into host cells;
[0025] (3) culturing the host cells described in step (2);
[0026] (4) harvesting the human replication-deficient recombinant adenovirus released from the cells in step (3);
[0027] (5) Expanding the culture of the recombinant adenovirus in step (4);
[0028] (6) Purify the culture product in step (5).
[0029] Another aspect of the present invention provides a recombinant adenovirus vector tuberculosis vaccine preparation, which contains a human replication-deficient recombinant adenovirus containing the polynucleotide, and the recombinant adenovirus is prepared as an injection or mucosal administration preparation.
[0030] Specifically, the preparation is a mucosal administration preparation, preferably including nasal mucosa, oral mucosa or pulmonary mucosa.
[0031] Specifically, the preparation is an inhalation preparation, which is inhaled through the nose or mouth, preferably, nasal drops, sprays, atomized inhalers or dry powder inhalers; more preferably, the inhalation preparation is a liquid inhalation preparation or a dry powder inhalation preparation.
[0032] Specifically, the vaccine further comprises pharmaceutically acceptable excipients, which include but are not limited to one or more of a buffer, a protective agent, a stabilizer, a surfactant, and an osmotic pressure regulator.
[0033] Specifically, the mucosal administration preparation is selected from: liquid dosage form, solid dosage form, semisolid dosage form; preferably, it is an aerosol, spray, nasal drops, powder mist, powder, gel, microsphere, liposome, film, suspension; more preferably, the mucosal administration preparation is a spray or atomized administration preparation.
[0034] Specifically, the content of the recombinant viral vector in the preparation combination is 1×10 8 ~1×10 12 VP / ml.
[0035] Specifically, the pharmaceutically acceptable excipients include but are not limited to: one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, an inactivator or human albumin; preferably, human serum albumin; the buffer includes but is not limited to one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes but is not limited to one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na) and magnesium chloride; the stabilizer includes but is not limited to one or more of sucrose, mannitol, fucose and maltose; the surfactant includes but is not limited to one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes but is not limited to sodium chloride or is omitted; preferably, the excipient components include mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
[0036] Specifically, the dosage form is an aerosol inhaler, and the vaccine is aerosolized by an aerosol delivery device to form particles with a particle size of less than 10 μm; preferably, 0.5 to 10 μm, more preferably, 5 to 10 μm.
[0037] Another aspect of the present invention provides a method for preparing a recombinant adenovirus vector pulmonary tuberculosis vaccine preparation, comprising the following steps: preparing a recombinant adenovirus vector encoding Mycobacterium tuberculosis antigen; and adding pharmaceutically acceptable excipients.
[0038] Specifically, a recombinant adenoviral vector encoding Mycobacterium tuberculosis Ag85A antigen is prepared, and optionally, a pharmaceutically acceptable excipient is added;
[0039] or,
[0040] preparing a recombinant adenoviral vector encoding Mycobacterium tuberculosis Mtb32A and Mtb39A antigens, and optionally adding a pharmaceutically acceptable excipient;
[0041] or,
[0042] preparing a recombinant adenoviral vector encoding Mycobacterium tuberculosis Mtb32A, Mtb39A and Ag85A antigens, and optionally adding a pharmaceutically acceptable excipient;
[0043] or,
[0044] Recombinant adenoviral vectors encoding Mycobacterium tuberculosis Ag85A antigen and recombinant adenoviral vectors encoding Mycobacterium tuberculosis Mtb32A and Mtb39A antigens (TB75K) are prepared separately, mixed, and optionally, a pharmaceutically acceptable excipient is added.
[0045] Specifically, the method comprises the following steps: constructing a fusion antigen sequence; constructing a plasmid; co-transfecting and packaging the obtained recombinant adenovirus shuttle plasmid and a backbone plasmid carrying most of the adenovirus genome;
[0046] Preferably, using genetic engineering methods,
[0047] Construct the Ag85A antigen sequence;
[0048] or,
[0049] Construct the Mtb32A and Mtb39A (TB75K) fusion antigen sequence;
[0050] Alternatively, the fusion antigen sequence containing Mtb32A and Mtb39A (TB75K) and the Ag85A antigen sequence are connected using a connecting peptide (i.e., a linker);
[0051] More preferably, the fusion antigen is constructed as TB75K-linker-Ag85A or Ag85A-linker-TB75K.
[0052] Specifically, the method further includes the following steps: adding corresponding auxiliary materials to the co-transfected and packaged original strain seeds to obtain the vaccine.
[0053] Specifically, the steps for constructing a recombinant adenovirus vector encoding the fusion antigen protein of Mycobacterium tuberculosis TB75K and Ag85A include:
[0054] (1) Construction of pDC316-TB75K-Ag85A and pDC316-Ag85A-TB75K plasmids
[0055] The synthesized TB75K and Ag85A fusion protein gene fragments were enzymatically digested and the digested fragments were recovered. Simultaneously, the shuttle plasmid vector of the AdMax adenovirus system was enzymatically digested and the vector was recovered. The TB75K-Ag85A fragment was ligated to the vector using homologous recombination, transformed into competent cells, and plated. A single clone was streaked and inoculated, and colony PCR was performed for identification. Subsequently, a single positive clone from the streaked plate was cultured, and the plasmid was extracted for enzymatic digestion identification. Ten clones identified as positive by enzymatic digestion were sequenced, and the vector identified as correct by sequencing was designated pDC316-TB75K-Ag85A.
[0056] (2) Recombinant adenovirus Ad5, TB75K, Ag85A virus seed packaging
[0057] The shuttle plasmids pDC316-TB75K-Ag85A, pDC316-Ag85A-TB75K and the backbone plasmid of the AdMax adenovirus system were co-transfected to package Ad5-TB75K-Ag85A and Ad5-Ag85A-TB75K.
[0058] Specifically, the present invention also provides a preparation method for a novel multi-component recombinant adenovirus vector pulmonary tuberculosis vaccine preparation composition and its application in preventing and / or treating diseases; preferably, the disease is pulmonary tuberculosis.
[0059] One aspect of the present invention provides a use of a formulation composition of a recombinant adenovirus vector tuberculosis vaccine in the preparation of a medicament for preventing and / or treating a disease; preferably, the disease is tuberculosis.
[0060] The term "antigen or immunogenic fragment" refers to a substance that is capable of stimulating the immune system to produce an immune response.
[0061] "Fusion antigen" refers to at least two heterologous antigens connected directly or through an amino acid linker. The fusion antigens can be in any order.
[0062] The beneficial effects of the present invention compared to the prior art are:
[0063] The immune composition of the present invention solves the problem that 1) the existing subcutaneous BCG and intramuscular tuberculosis vaccines cannot induce high-level immune responses in the body through the three antigens of Mycobacterium tuberculosis; and 2) by screening antigen combinations among numerous tuberculosis antigens, without affecting antigen expression, to achieve mutual promotion of immune responses and comprehensively improve immune effects.
[0064] Another aspect of the present invention provides a vector expressing a fusion antigen that, upon immunization, induces high levels of antigen-specific antibodies and produces a robust cellular immune response. Furthermore, the immune composition of the present invention can generate high levels of cellular immune responses both in the lungs and throughout the body. The adenovirus vector-based recombinant tuberculosis vaccine provided by the present invention exhibits excellent stability, safety, and efficacy.
[0065] In one aspect of the present invention, the vaccine formulation is administered via respiratory mucosal delivery, which not only improves compliance but also provides a lower dosage than injection, and can produce a triple immune effect of humoral immunity, cellular immunity, and mucosal immunity. The vaccine composition provided by the present invention can be used for primary or booster immunization.
[0066] In one aspect of the present invention, the vaccine, after atomization by suitable equipment, can produce aerosol particles with a uniform particle size of 3 to 10 μm, preferably 5 to 10 μm. These particles can be inhaled through the nasal or oral cavity and reach the lungs, thereby generating a protective immune response throughout the respiratory tract and lungs, enhancing the effective utilization rate and effectiveness of the vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1. Antigen expression test results
[0068] Figure 2. Antigen-specific IFN-γ detection results in spleen cells of the injection group (2 weeks)
[0069] Figure 3. Antigen-specific IFN-γ detection results in spleen cells of the injection group (4 weeks)
[0070] Figure 4. Detection results of TB75K-specific cytokines in spleen cells of the inhalation group
[0071] Figure 5. Detection results of TB75K-specific CD4+ T cell factors in lung lavage fluid of the inhalation group
[0072] Figure 6. Detection results of TB75K-specific CD8+ T cell factors in lung lavage fluid of the inhalation group
[0073] Figure 7. Detection results of Ag85A-specific cytokines in spleen cells of the inhalation group
[0074] Figure 8. Detection results of Ag85A-specific CD4+ T cell factors in lung lavage fluid of the inhalation group
[0075] Figure 9. Detection results of Ag85A-specific CD8+ T cell factors in lung lavage fluid of the inhalation group
[0076] Figure 10. Detection results of Rv3425-specific cytokines in spleen cells of the inhalation group
[0077] Figure 11. Detection results of CD4T-specific cytokines in lung lavage fluid of the inhalation group
[0078] Figure 12. Detection results of CD8T-specific cytokines in lung lavage fluid of the inhalation group
[0079] Figure 13. Fusion antigen virus titer test results
[0080] Figure 14. IFN-γ detection results of spleen cells in the fusion antigen injection group
[0081] Figure 15. TB75K-specific IFN-γ detection results in splenocytes of the fusion antigen inhalation group
[0082] Figure 16. TB75K-specific CD4+ T cell detection results in the fusion antigen inhalation group
[0083] Figure 17. TB75K-specific CD8+ T cell detection results in the fusion antigen inhalation group
[0084] Figure 18. Results of Ag85A-specific IFN-γ detection in splenocytes of the fusion antigen inhalation group
[0085] Figure 19. Ag85A-specific CD4+ T cell detection results in the fusion antigen inhalation group
[0086] Figure 20. Ag85A-specific CD8+ T cell detection results in the fusion antigen inhalation group DETAILED DESCRIPTION
[0087] The present invention will be further described in detail below in conjunction with specific embodiments. The examples provided are only for illustrating the present invention and are not intended to limit the scope of the present invention. The examples provided below can serve as a guide for further improvements by those skilled in the art and are not intended to limit the present invention in any way.
[0088] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.
[0089] Example 1: Packaging of recombinant adenovirus tuberculosis vaccine
[0090] (1) Construction of pDC316-Ag85A (SEQ ID NO: 1), pDC316-TB75K (SEQ ID NO: 2), pDC316-Rv3425 (SEQ. NO: 31), pDC316-Ag85A-TB75K (SEQ ID NO: 3), and pDC316-TB75K-Ag85A (SEQ ID NO: 1) plasmids. The synthesized TB75K, Ag85A, and Rv3425 gene fragments were digested with enzymes and the digested fragments were recovered. At the same time, the shuttle plasmid vector of the AdMax adenovirus system was digested with enzymes and the vector was recovered. The TB75K, Ag85A, and Rv3425 fragments were connected to the vector using homologous recombination, transformed into competent cells, and plated on Amp-resistant LB plates. The next day, a single clone was picked for streak inoculation and colony PCR identification was performed. Subsequently, a single positive clone from the streak plate was cultured, and the plasmid was extracted for enzyme digestion identification. Ten positive clones identified by enzyme digestion were sequenced and the vectors identified by sequencing were recorded as pDC316-Ag85A, pDC316-TB75K, and pDC316-Rv3425. (2) Packaging of recombinant adenovirus Ad5-TB75K, Ad5-Ag85A, and Ad5-Rv3425 virus seeds
[0091] The shuttle plasmids pDC316-Ag85A, pDC316-TB75K, pDC316-Rv3425 and the backbone plasmid of the AdMax adenovirus system were packaged by co-transfection. The packaged viruses were named Ad5-TB75K, Ad5-Ag85A, and Ad5-Rv3425.
[0092] Preparation of vaccine inhalation / injection formulations:
[0093] Take the above new recombinant adenovirus stock solution (containing 5×10 10 VP), add excipients and mix to obtain recombinant tuberculosis vaccine (adenovirus type 5 vector) preparation.
[0094] Example 2: In vitro expression and identification test of recombinant adenovirus vector
[0095] The expression of the target antigen of the recombinant adenovirus vector prepared in Example 1 was detected by cell assay combined with Western Blot.
[0096] Western Blot assay to detect target gene expression
[0097] Electrophoresis, transfer, blocking, primary antibody incubation, and secondary antibody incubation.
[0098] Result Analysis
[0099] 1) Test establishment conditions
[0100] a. The negative control sample should not have the target antigen band;
[0101] b. The target antigen bands of positive samples are clearly discernible and have accurate molecular weights.
[0102] 2) Judgment criteria
[0103] The TB75K antigen protein has a target band near 75kDa, and the negative control should not have the target protein band, which is determined to be positive for target protein expression.
[0104] The Ag85A antigen protein has a target band near 32kDa, and the negative control should not have a target protein band, which is determined to be positive for target protein expression.
[0105] The Rv3425 antigen protein has a target band near 20 kDa, and the negative control should not have a target protein band, which is determined to be positive for target protein expression.
[0106] The test results are shown in Figure 1.
[0107] Example 3: Immunity Levels of Recombinant Adenovirus Vector Tuberculosis Vaccine
[0108] Five weeks after the initial immunization with BCG subcutaneous injection, 6-8 week-old female C57BL / 6 mice were boosted with the recombinant adenovirus vector tuberculosis vaccine (Ad5-TB75K, Ad5-Ag85A, Ad5-Rv3425) prepared in Example 2 by injection or inhalation. 8 C57BL / 6 mice per group were injected with a dose of 1×10 9 IFU / mouse, inhalation immunization dose is 1×10 7 IFU / rat; booster immunization was performed once. Splenocytes were collected from the injection group 2 and 4 weeks after the booster immunization to measure the levels of antigen-specific cytokines in splenocytes. Serum, lung lavage fluid, and splenocytes were collected from the inhalation group 4 weeks after the booster immunization to measure the levels of antigen-specific cytokines in lung lavage fluid and splenocytes.
[0109] The specific vaccination schedule is shown in Table 1 and Table 2:
[0110] Injection group:
[0111] Table 1. Vaccination method of injection group
[0112] Inhalation group:
[0113] Table 2. Inoculation method of the inhalation group
[0114] The immune response results of the injection group are shown in Table 3 and Figures 2 and 3:
[0115] Table 3. Antigen-specific IFN-γ detection results in spleen cells of the injection group (2 weeks and 4 weeks)
[0116] The immune response results of the inhalation group are shown in Tables 4-6 and Figures 4-12:
[0117] Table 4. Mean results of TB75K-specific cytokine detection in the inhalation group
[0118] Table 5. Results of Ag85A-specific cytokine detection in the inhalation group
[0119] Table 6. Specific cytokine detection results of Rv3425 inhalation group
[0120] The data after intramuscular injection and inhalation immunization showed that the Ag85A-specific immunity and TB75K-specific immunity induced by group 4 were significantly higher than those in other groups, and had a mutually reinforcing effect.
[0121] Example 4: Packaging of multivalent recombinant adenovirus tuberculosis vaccine
[0122] (1) Construction of pDC316-Ag85A-TB75K, pDC316-TB75K6-Ag85A, pDC316-Ag85A-Rv3425, and pDC316-Rv3425-Ag85A plasmids
[0123] The synthesized Ag85A-TB75K, TB75K6-Ag85A, Ag85A-Rv3425, and Rv3425-Ag85A gene fragments were enzymatically digested and the digested fragments were recovered. Simultaneously, the shuttle plasmid vector of the AdMax adenovirus system was enzymatically digested and the vector recovered. Using homologous recombination, the Ag85A-TB75K, TB75K6-Ag85A, Ag85A-Rv3425, and Rv3425-Ag85A fragments were ligated to the vector, transformed into competent cells, and plated onto Amp-resistant LB plates. The next day, single colonies were streaked and inoculated, and colony PCR was performed for identification. Subsequently, single positive colonies from the streaked plates were cultured, and plasmids were extracted for enzymatic identification. Ten positive clones identified by enzyme digestion were selected for sequence determination, and the vectors identified correctly by sequencing were recorded as pDC316-Ag85A-TB75K, pDC316-TB75K6-Ag85A, pDC316-Ag85A-Rv3425, and pDC316-Rv3425-Ag85A.
[0124] (2) Packaging of recombinant adenovirus Ag85A-TB75K, TB75K6-Ag85A, Ag85A-Rv3425, and Rv3425-Ag85A
[0125] The shuttle plasmids pDC316-Ag85A-TB75K, pDC316-TB75K6-Ag85A, pDC316-Ag85A-Rv3425, pDC316-Rv3425-Ag85A and the backbone plasmid of the AdMax adenovirus system were packaged by co-transfection, and the packaged viruses were named Ad5-Ag85A-TB75K, Ad5-TB75K-Ag85A, Ad5-Ag85A-Rv3425, and Ad5-Rv3425-Ag85A.
[0126] Preparation of vaccine inhalation / injection formulations:
[0127] Take the above new recombinant adenovirus stock solution (containing 5×10 10 VP), add excipients and mix to obtain recombinant tuberculosis vaccine (adenovirus type 5 vector) preparation.
[0128] Virus titer detection method and test results
[0129] Virus titer assay: Dilute the recombinant adenovirus stock solution prepared above to an appropriate dilution factor and add 50 μl / well to 500 μl of HEK293 cells. Incubate in a 37°C incubator for 48 hours. After incubation, fix the cells with methanol. Incubate with primary and secondary antibodies and develop color according to the kit instructions. After development, add 500 μl of PBS solution to each well and count the diseased cells under a microscope. Select 16 fields of view for each dilution of each sample. Calculate the mean number of diseased cells in each 16 fields of view and use this value to calculate the virus titer of the sample.
[0130] The test results are shown in Table 7 and Figure 13
[0131] Table 7. Fusion antigen virus titer test results
[0132] Example 5: Immune Levels of Multivalent Recombinant Adenovirus Vector Tuberculosis Vaccine
[0133] Five weeks after a primary immunization with BCG subcutaneously, 6-8 week-old female C57BL / 6 mice were boosted with the recombinant adenovirus vector tuberculosis vaccine formulations prepared in Examples 2 and 4 (Ad5-Ag85A-TB75K, Ad5-TB75K-Ag85A, and Ad5-Ag85A and Ad5-TB75K (1:1)) by injection or inhalation. Eight C57BL / 6 mice were included in each group, and the injection immunization dose was 1×109 IFU / mouse. The inhalation immunization dose is 1×10 7 IFU / rat; booster immunization was performed once. Four weeks after the booster immunization, spleen cells were collected from the injection group and the antigen-specific cytokine levels in spleen cells were measured. Lung lavage fluid and spleen cells were collected from the inhalation group and the antigen-specific cytokine levels in lung lavage fluid and spleen cells were measured.
[0134] The specific vaccination schedule is shown in Tables 8 and 9:
[0135] Injection group:
[0136] Table 8. Vaccination schedule for fusion antigen injection group
[0137] Inhalation group:
[0138] Table 9. Vaccination schedule for the fusion antigen inhalation group
[0139] The immunization results of the injection group are shown in Table 10 and Figure 14 below:
[0140] Table 10. IFN-γ detection results of spleen cells in the fusion antigen injection group
[0141] The immunization results of the inhalation group are shown in Tables 11-12 and Figures 15-20
[0142] Table 11. TB75K specific cytokine detection results in the fusion antigen inhalation group
[0143] Table 12. Results of Ag85A-specific cytokine detection in the fusion antigen inhalation group
[0144] The data showed that Group 1 and Group 2 had better overall immune levels.
[0145] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.
[0146] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. An immunogenic composition comprising Mycobacterium tuberculosis Mtb32A antigen or an immunogenic fragment thereof, Mtb39A antigen or an immunogenic fragment thereof and Ag85A antigen or an immunogenic fragment thereof.
2. The immunogenic composition according to claim 1, characterized in that The Mtb32A and Mtb39A are fusion antigens (TB75K).
3. The immunogenic composition according to claim 1 or 2, characterized in that Mtb32A, Mtb39A and Ag85A are fusion antigens.
4. The immunogenic composition according to claim 3, characterized in that The Ag85A is fused with Mtb32A and Mtb39A (TB75K) via a linker; preferably, it is Ag85A-linker-TB75K or TB75K-linker-Ag85A.
5. Use of the immunogenic composition according to any one of claims 1 to 4 in the preparation of a medicament for preventing and / or treating a disease.
6. A polynucleotide molecule, characterized in that The nucleic acid molecules include nucleic acid molecules encoding Ag85A antigen or immunogenic fragments thereof, nucleic acid molecules encoding Mtb32A antigen or immunogenic fragments thereof, and nucleic acid molecules encoding Mtb39A antigen or immunogenic fragments thereof.
7. The polynucleotide molecule according to claim 6, characterized in that Application in the preparation of drugs for preventing and / or treating diseases.
8. A vector comprising the polynucleotide molecule according to claim 6.
9. The carrier according to claim 8, characterized in that The vector is a replication-deficient recombinant adenovirus; the adenovirus is a human adenovirus or a chimpanzee adenovirus; preferably, the human adenovirus is one or more selected from human adenoviruses of serotypes 1 to 57; more preferably, the human adenovirus is human adenovirus of serotypes 5, 26 or 35.
10. Use of the carrier according to claim 8 or 9 in the preparation of a drug for preventing and / or treating a disease.
11. A method for preparing the recombinant adenovirus according to claim 9, the method comprising the following steps: (1) constructing a shuttle plasmid vector containing the polynucleotide molecule encoding the tuberculosis antigen peptide or its immunogenic fragment; (2) transfecting the shuttle plasmid vector described in step (1) together with the backbone plasmid into a host cell; (3) culturing the host cell described in step (2); (4) harvesting the human replication-deficient recombinant adenovirus released from the cells in step (3); (5) expanding the culture of the recombinant adenovirus in step (4); (6) Purify the culture product in step (5).
12. A recombinant adenovirus vector tuberculosis vaccine preparation, characterized in that: A human replication-deficient recombinant adenovirus containing the polynucleotide of claim 11, wherein the recombinant adenovirus is prepared as an injection or a mucosal administration preparation.
13. The recombinant adenovirus vector tuberculosis vaccine preparation according to claim 12, wherein the mucosal administration preparation comprises nasal mucosa, oral mucosa or pulmonary mucosa.
14. The recombinant adenovirus vector tuberculosis vaccine preparation according to claim 13, wherein the mucosal administration preparation is an inhalation administration preparation, which is nasal inhalation or oral inhalation, preferably, nasal drops, sprays, atomized inhalations or dry powder inhalations; more preferably, the inhalation administration preparation is a liquid inhalation preparation or a dry powder inhalation preparation.
15. The recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 12 to 14, characterized in that: The vaccine further comprises pharmaceutically acceptable excipients, which include but are not limited to: one or more of a buffer, a protective agent, a stabilizer, a surfactant, and an osmotic pressure regulator.
16. The recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 12 to 15, characterized in that: The mucosal administration preparation is selected from: liquid dosage form, solid dosage form, semisolid dosage form; preferably aerosol, spray, nasal drops, powder mist, powder, gel, microsphere, liposome, film, suspension; more preferably, the mucosal administration preparation is a spray or atomized administration preparation.
17. The recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 12 to 16, characterized in that: The pharmaceutically acceptable excipients include but are not limited to: one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, an inactivator or human albumin; preferably, human albumin; the buffer includes but is not limited to one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes but is not limited to one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na) and magnesium chloride; the stabilizer includes but is not limited to one or more of sucrose, mannitol, fucose and maltose; the surfactant includes but is not limited to one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes but is not limited to sodium chloride or is omitted; preferably, the excipient components include mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
18. The recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 12 to 17, characterized in that: The dosage form is an aerosol inhalation, and the vaccine is aerosolized by an aerosol drug delivery device to form particles with a particle size of less than 10 μm; preferably, 0.5 to 10 μm, and more preferably, 5 to 10 μm.
19. A method for preparing the recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 12 to 18, characterized in that: The following steps are involved: A recombinant adenovirus vector encoding Mycobacterium tuberculosis antigen is prepared; and pharmaceutically acceptable excipients are added.
20. The method for preparing the recombinant adenovirus vector tuberculosis vaccine preparation according to claim 19, characterized in that: preparing a recombinant adenoviral vector encoding Mycobacterium tuberculosis Ag85A antigen, and optionally adding a pharmaceutically acceptable excipient; or, preparing a recombinant adenoviral vector encoding Mycobacterium tuberculosis Mtb32A and Mtb39A antigens, and optionally adding a pharmaceutically acceptable excipient; or, preparing a recombinant adenoviral vector encoding Mycobacterium tuberculosis Mtb32A, Mtb39A and Ag85A antigens, and optionally adding a pharmaceutically acceptable excipient; or, Recombinant adenoviral vectors encoding Mycobacterium tuberculosis Ag85A antigen and recombinant adenoviral vectors encoding Mycobacterium tuberculosis Mtb32A and Mtb39A antigens are prepared separately, mixed, and optionally, a pharmaceutically acceptable excipient is added.
21. The method for preparing the recombinant adenovirus vector tuberculosis vaccine preparation according to claim 20, characterized in that: The method comprises the following steps: constructing a fusion antigen sequence; constructing a plasmid; and co-transfecting and packaging the obtained recombinant adenovirus shuttle plasmid and a backbone plasmid carrying most of the adenovirus genome.
22. The method for preparing the recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 17 to 21, characterized in that: The following steps are also included: The vaccine is obtained by adding corresponding auxiliary materials to the co-transfected and packaged original strain seeds.
23. Use of the recombinant adenovirus vector tuberculosis vaccine preparation according to any one of claims 19 to 22 in the preparation of a medicament for preventing and / or treating a disease; preferably, the disease is tuberculosis.
